Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association between heavy metals and risk of cardiovascular diseases in US adults with prediabetes from NHANES 2011-2018.
BMC Public Health
January 2025
Department of Epidemiology and Biostatistics, School of Public Health of Jilin University, Changchun, 130021, China.
Background: The association of plasma metals on the risk of cardiovascular diseases (CVD) in adults with prediabetes remains poorly investigated. To assess the association between plasma metal exposure and the risk of CVD in prediabetic adults in the United States using five plasma metals.
Methods: Five cycles of data (2011-2012, 2013-2014, 2015-2016, and 2017-2018) from the NHANES were adopted in this study.
Phytotoxic impact of di-butyl phthalate (DBP) on physiological, biochemical, and oxidative stress parameters of rice (Oryza sativa).
Environ Sci Pollut Res Int
January 2025
Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.
Phthalates are synthetic compounds, well-known plasticizers, with numerous applications and reported to have adverse effects on all living organisms residing in terrestrial and aquatic environments. In this study, the rice (Oryza sativa) seedlings were exposed to di-butyl phthalate (DBP) exogenously for 7 days, with varying concentrations of 0, 200, 400, 800, and 1600 mg/L, to explore the toxicological, physiological, and biochemical consequences by measuring various parameters such as pigment, lipid, and HO (hydrogen peroxide) contents. The biochemical analysis of seedlings showed that the pigments, lipids, and HO concentrations were altered abnormally.
View Article and Find Full Text PDFSimple model for predicting the awakening propofol plasma concentration during target-controlled infusion with the Marsh model.
Br J Anaesth
January 2025
School of Electrical and Computer Engineering, University of Sydney, Sydney, NSW, Australia.
Uncovering the impact of COVID-19-mediated bidirectional dysregulation of cytochrome P450 3A4 on systemic and pulmonary drug concentrations using physiologically based pharmacokinetic modeling.
Drug Metab Dispos
January 2025
Current affiliation: Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; Current affiliation: OneDrug Inc., Toronto, Ontario, Canada; Program in Translational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada; Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, United Kingdom. Electronic address:
Several clinical studies have shown that COVID-19 increases the systemic concentration of drugs in hospitalized patients with COVID-19. However, it is unclear how COVID-19-mediated bidirectional dysregulation of hepatic and pulmonary cytochrome P450 (CYP) 3A4 affects drug concentrations, especially in the lung tissue, which is most affected by the disease. Herein, physiologically based pharmacokinetic modeling was used to demonstrate the differences in systemic and pulmonary concentrations of 4 respiratory infectious disease drugs when CYP3A4 is concurrently downregulated in the liver and upregulated in the lung based on existing clinical data on COVID-19-CYP3A4 interactions at varying severity levels including outpatients, non-intensive care unit (ICU), and ICU patients.
View Article and Find Full Text PDFImpact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study.
Nefrologia (Engl Ed)
January 2025
Department of Hemodialysis, Hospital General Regional No. 58, Mexican Institute of Social Security, León, Guanajuato, Mexico.
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis.
Objective: To investigate the impact of iron chelation on telomere length, oxidative stress, and ferritin levels in patients undergoing hemodialysis.
Methods: This is an open-label study, with a control group of patients undergoing hemodialysis, who will receive treatment with deferasirox 15mg/kg/day for 6 months for iron chelation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!